The treatment of HER2+ breast cancer includes the administration of chemotherapy and trastuzumab, a monoclonal antibody against the HER2 receptor (Abal et al., 2003; Harbeck and Gnant, 2017; Waks and Winer, 2019). The gene discussed is ERBB2; the disease is breast carcinoma.